Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

NICE recommends lenalidomide for treating blood disorders

  • Comment

NICE has issued final draft guidance recommending lenalidomide, an immunomodulatory drug also known as Revlimid, as an option for treating myelodysplastic syndromes (MDS).

Lenalidomide works primarily by modifying the way that the immune system works to aid the sufferer.

The appraisal leading to the NICE guidance focused on the use of lenalidomide for treating people with a specific type of MDS that is characterised by an isolated deletion 5q cytogenetic abnormality.

If accepted this guidance would represent a step forward for treatment of people with MDS who generally receive best supportive care, including regular blood transfusions, as there are few specifically definable treatment options available.

Consideration of new options for treating MDS is important as this type of bone marrow disorder, which affects 2000 people each year in England, can lead to life threatening diseases such as acute myeloid leukaemia (AML) and increased infection rates.

Sir Andrew Dillon

Sir Andrew Dillon

Lenalidomide is already used to treat a variety of myeloma type cancers and may also help to prevent development of AML.

Commenting on the final draft guidance, NICE chief executive Sir Andrew Dillon said: “The committee heard from clinical experts that lenalidomide is an effective therapy. Celgene – who market lenalidomide – worked with us to provide enough evidence to make it possible for us to recommend it for this group of people.

“Celgene provided a revised analysis and further information on their proposal for a reduction in the cost of the drug to the NHS (through the patient access scheme),” he said.

Celgene’s patient access scheme involves the NHS paying for lenalidomide treatment for up to 26 monthly cycles.

The company will then provide the drug free of charge for those people who receive more than 26 monthly cycles.

The draft guidance is now with consultees, who have the opportunity to appeal against it. NICE advises that NHS bodies should make decisions locally on the funding of specific treatments until final guidance is issued.


  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.